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need for additional well-characterized antibodies to Lrrk2 to
further study the biology of this enzyme.
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Low Incidence for Predementia and Dementia
Syndromes in a Brain Imaging Study
Francesco Panza, MD, PhD,1
Cristiano Capurso, MD, PhD,2 Angelo Del Parigi, MD,3
Alessia d’Introno, PhD,1 Anna M. Colacicco, PhD,1
Antonio Capurso, MD,1
and Vincenzo Solfrizzi, MD, PhD1
Jagust and colleagues1 performed positron emission tomog-
raphy using [18F]fluorodeoxyglucose and structural magnetic
resonance imaging at baseline in 60 cognitively normal
community-dwelling older subjects who were part of a lon-
gitudinal cohort study Sacramento Area Latino Study on Ag-
ing (SALSA) project. Subjects were followed for a mean of
3.8 years, and only six subjects developed incident dementia
or cognitive impairment (converters). The results of Jagust
and colleagues’ study1 indicate that temporal and parietal
glucose metabolism predict decline in global cognitive func-
tion, and medial temporal brain volumes predict memory de-
cline in normal older people, suggesting detection of preclin-
ical Alzheimer’s disease pathology. The crude incidence rate
for cognitive impairment with no dementia and dementia
was 26 per 1,000 person-years.1 The authors reported in the
Discussion section of their article1 that other population-
based studies found similar incidence rates of cognitive im-
pairment.2–4 Currently, we are aware of only a few incidence
studies on predementia syndromes applying mild cognitive
impairment (MCI) and not cognitive impairment with no
dementia criteria.5 In the Italian Longitudinal Study on Ag-
ing (ILSA), a population-based study with a 3.5-year follow-
up, involving a total of 2,963 individuals, aged 65 to 84
years, we found an estimated incidence rate of 21.5 per
1,000 person-years for MCI, which is therefore higher than
the incidence rate of MCI and MCI-modified (ie, 8.5/1,000
and 12.2/1,000 person-years) found in the Leipzig Longitu-
dinal Study of the Aged (LEILA75 study).5 In the Per-
sonnes Agees Quid (PAQUID) study, a French population-
based cohort of 3,777 elderly people, aged 65 years and
older, the global incidence rate of MCI was 9.9/1,000
person-years.5 Finally, in a Finnish population-based study,
the global incidence rate of MCI was 25.94/1,000 person-
years.5 But these population-based studies reported the inci-
dence rates for MCI, and not for conversion, that is, normal
subjects who progressed to cognitive impairment with no de-
mentia (n  5) and Alzheimer’s disease (n  1).1 In fact, in
the ILSA, the incidence rate for conversion (MCI plus de-
mentia) was 34 per 1,000 person-years, which is therefore
higher than the incidence rate of converters in the SALSA
project. The other two population-based studies cited in the
Discussion section of Jagust and colleagues’ article1 reported
only the crude overall incidence rates for all dementias with
Clinical Dementia Rating scale  0.5 (25.5/1,000 person-
years)3 and the incidence rate for dementia and Alzheimer’s
disease (25.5/1,000 and 16.8/1,000 person-years, respective-
ly).4 In conclusion, we suggest that the low incidence rates
for conversion in the SALSA project could limit, as acknowl-
edged in the report by the authors, the potential ability to
generalize the interesting results of the study.
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Reply
William J. Jagust, MD,1,2 Dan Mungas, PhD,3
and Mary N. Haan, DrPH4
We thank Dr Panza and colleagues for an insightful read-
ing of our article concerning the ability of [18F]-
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fluorodeoxyglucose positron emission tomography scanning
to predict cognitive decline in a group of subjects selected
from the Sacramento Area Latino Study on Aging (SALSA)
cohort.1 We agree that there are few other studies with
which to compare our own results. The published articles
cited by Dr Panza include estimates of incidence ranging
from 8.5 to 26 per 1,000 person-years for mild cognitive
impairment (MCI) syndromes. We also agree that the most
appropriate figure for comparison with our own data would
be incidence of MCI or cognitive impairment/no dementia
combined with incidence of dementia, as indeed we reported
the “conversion” from normal to both of these states. The
authors cite their own data from the Italian Longitudinal
Study on Aging in this regard as 34 per 1,000 person-years.
Although we did quote published incidence rates for demen-
tia from two population-based studies, it is also worth noting
that published dementia incidence rates vary widely, from
10.7 to more than 30 per 1,000 person-years.2 Given the
large variability in methodology, populations, and the diffi-
culties in establishing and differentiating MCI, cognitive im-
pairment/no dementia, Alzheimer’s disease, and other de-
mentias, the threefold differences in estimates of MCI or
dementia incidence are not surprising. In this light, we are
more impressed with the similarity than the difference of our
crude incidence rate of 26 per 1,000 to the figure of 34 per
1,000 person-years that Dr Panza and colleagues reported.
However, our study was not designed to determine the
incidence of cognitive impairment/no dementia or dementia.
The subjects were a subsample of a larger cohort, may not
reflect the incidence in the entire cohort, and are a relatively
small group from which to draw firm conclusions about in-
cidence rates. Incident disease or conversion was not an out-
come measure in our study, which used cognitive decline as
a continuous variable. We presented incidence data to make
a simple point: Because the rate of conversion was not un-
usually high, the subjects were not already in an early stage
of dementia. Such an incidence rate would thus bias against
finding a predictive value to positron emission tomography
imaging, making the tests of our hypotheses more conserva-
tive. Although generalizability is always a concern in small
samples, we believe that this is the appropriate sort of cohort
in which to test the predictive value of imaging.
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Adherence to a Mediterranean Dietary Pattern and
Risk of Alzheimer’s Disease
Vincenzo Solfrizzi, MD, PhD,1
Cristiano Capurso, MD, PhD,2
and Francesco Panza, MD, PhD1
Scarmeas and colleagues1 reported the results of a
community-based study involving 2,258 nondemented indi-
viduals in New York, in which adherence to a traditional
Mediterranean diet was associated with significant reduction
in risk for Alzheimer’s disease. These authors reported that
the typical dietary pattern of the Mediterranean diet is char-
acterized by high intakes of vegetables, fruits and nuts, le-
gumes, cereals, fish, and monounsaturated fat; relatively low
intakes of meat and dairy products; and moderate consump-
tion of alcohol. In fact, higher levels of consumption of olive
oil are considered the hallmark of the traditional Mediterra-
nean diet. The use of olive oil now extends beyond the Med-
iterranean region. In particular, monounsaturated fatty acids,
consequent to the high consumption of extra virgin olive oil,
represent the most important fat in the Mediterranean diet.
Cumulative evidence suggests that extra virgin olive oil may
have a role in the protection against cognitive decline, in
addition to protection other than against coronary disease
and several types of cancer, because of its high levels of
monounsaturated fatty acids and polyphenolic com-
pounds.2,3 However, in Table 1 of Scarmeas and colleagues’
article,1 the median daily intake of monounsaturated fatty
acids to saturated fatty acids ratio for individual food cate-
gories by Mediterranean diet score tertiles was 1 and in
overall about 2.5 times lower than the same value calculated
from other studies of the Mediterranean diet.3,4 Scarmeas
and colleagues1 did not provide any possible explanation for
these important differences. In conclusion, Scarmeas and col-
leagues’ study1 provides another reminder that the preserva-
tion of certain dietary and lifestyle traditions may have im-
portant health consequences, and that the advantages of the
Mediterranean diet are transferable to other populations, but
unfortunately one of the hallmarks of this dietary pattern
may be not fulfilled in this study population.
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